190 related articles for article (PubMed ID: 10901448)
1. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
Bangard M; Béhé M; Guhlke S; Otte R; Bender H; Maecke HR; Biersack HJ
Eur J Nucl Med; 2000 Jun; 27(6):628-37. PubMed ID: 10901448
[TBL] [Abstract][Full Text] [Related]
2. A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide.
Breeman WA; Hofland LJ; van der Pluijm M; van Koetsveld PM; de Jong M; Setyono-Han B; Bakker WH; Kwekkeboom DJ; Visser TJ; Lamberts SW
Eur J Nucl Med; 1994 Apr; 21(4):328-35. PubMed ID: 7911760
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo evaluation of copper-64-octreotide conjugates.
Anderson CJ; Pajeau TS; Edwards WB; Sherman EL; Rogers BE; Welch MJ
J Nucl Med; 1995 Dec; 36(12):2315-25. PubMed ID: 8523125
[TBL] [Abstract][Full Text] [Related]
4. In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats.
Bakker WH; Krenning EP; Reubi JC; Breeman WA; Setyono-Han B; de Jong M; Kooij PP; Bruns C; van Hagen PM; Marbach P
Life Sci; 1991; 49(22):1593-601. PubMed ID: 1658516
[TBL] [Abstract][Full Text] [Related]
5. [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation.
Bakker WH; Albert R; Bruns C; Breeman WA; Hofland LJ; Marbach P; Pless J; Pralet D; Stolz B; Koper JW
Life Sci; 1991; 49(22):1583-91. PubMed ID: 1658515
[TBL] [Abstract][Full Text] [Related]
6. Intraoperative detection of somatostatin-receptor-positive neuroendocrine tumours using indium-111-labelled DTPA-D-Phe1-octreotide.
Wangberg B; Forssell-Aronsson E; Tisell LE; Nilsson O; Fjalling M; Ahlman H
Br J Cancer; 1996 Mar; 73(6):770-5. PubMed ID: 8611378
[TBL] [Abstract][Full Text] [Related]
7. The octreotide suppression test and [111In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment.
Shi W; Buchanan KD; Johnston CF; Larkin C; Ong YL; Ferguson R; Laird J
Clin Endocrinol (Oxf); 1998 Mar; 48(3):303-9. PubMed ID: 9578820
[TBL] [Abstract][Full Text] [Related]
8. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy.
de Jong M; Bakker WH; Krenning EP; Breeman WA; van der Pluijm ME; Bernard BF; Visser TJ; Jermann E; Béhé M; Powell P; Mäcke HR
Eur J Nucl Med; 1997 Apr; 24(4):368-71. PubMed ID: 9096086
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1]-octreotide.
Westlin JE; Janson ET; Arnberg H; Ahlström H; Oberg K; Nilsson S
Acta Oncol; 1993; 32(7-8):783-6. PubMed ID: 8305227
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.
Krenning EP; Kwekkeboom DJ; Bakker WH; Breeman WA; Kooij PP; Oei HY; van Hagen M; Postema PT; de Jong M; Reubi JC
Eur J Nucl Med; 1993 Aug; 20(8):716-31. PubMed ID: 8404961
[TBL] [Abstract][Full Text] [Related]
11. Localization of metastatic gastroenteropancreatic tumours by somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-octreotide.
Hammond PJ; Arka A; Peters AM; Bloom SR; Gilbey SG
Q J Med; 1994 Feb; 87(2):83-8. PubMed ID: 8153292
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo studies of three radiolabelled somatostatin analogues: 123I-octreotide (OCT), 123I-Tyr-3-OCT and 111In-DTPA-D-Phe-1-OCT.
Virgolini I; Angelberger P; Li S; Yang Q; Kurtaran A; Raderer M; Neuhold N; Kaserer K; Leimer M; Peck-Radosavljevic M; Scheithauer W; Niederle B; Eichler HG; Valent P
Eur J Nucl Med; 1996 Oct; 23(10):1388-99. PubMed ID: 8781146
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor scintigraphy in central nervous system tumors: role of blood-brain barrier permeability.
Haldemann AR; Rösler H; Barth A; Waser B; Geiger L; Godoy N; Markwalder RV; Seiler RW; Sulzer M; Reubi JC
J Nucl Med; 1995 Mar; 36(3):403-10. PubMed ID: 7884502
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides.
Vallabhajosula S; Moyer BR; Lister-James J; McBride BJ; Lipszyc H; Lee H; Bastidas D; Dean RT
J Nucl Med; 1996 Jun; 37(6):1016-22. PubMed ID: 8683294
[TBL] [Abstract][Full Text] [Related]
15. Studies on radiolabeled somatostatin analogues in rats and in patients.
Breeman WA; Bakker WH; De Jong M; Hofland LJ; Kwekkeboom DJ; Kooij PP; Visser TJ; Krenning EP
Q J Nucl Med; 1996 Sep; 40(3):209-20. PubMed ID: 8961800
[TBL] [Abstract][Full Text] [Related]
16. [Somatostatin receptor scintigraphy in medullary thyroid carcinomas, GEP and carcinoid tumors].
Eising EG; Farahati J; Bier D; Knust EJ; Reiners C
Nuklearmedizin; 1995 Feb; 34(1):1-7. PubMed ID: 7724358
[TBL] [Abstract][Full Text] [Related]
17. Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide.
Ur E; Bomanji J; Mather SJ; Britton KE; Wass JA; Grossman AB; Besser GM
Clin Endocrinol (Oxf); 1993 May; 38(5):501-6. PubMed ID: 8101146
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.
Krenning EP; Bakker WH; Kooij PP; Breeman WA; Oei HY; de Jong M; Reubi JC; Visser TJ; Bruns C; Kwekkeboom DJ
J Nucl Med; 1992 May; 33(5):652-8. PubMed ID: 1349039
[TBL] [Abstract][Full Text] [Related]
19. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake.
Bernard BF; Krenning EP; Breeman WA; Rolleman EJ; Bakker WH; Visser TJ; Mäcke H; de Jong M
J Nucl Med; 1997 Dec; 38(12):1929-33. PubMed ID: 9430472
[TBL] [Abstract][Full Text] [Related]
20. [111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment.
Janson ET; Westlin JE; Eriksson B; Ahlström H; Nilsson S; Oberg K
Eur J Endocrinol; 1994 Dec; 131(6):577-81. PubMed ID: 7804439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]